JP2009544703A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009544703A5 JP2009544703A5 JP2009521795A JP2009521795A JP2009544703A5 JP 2009544703 A5 JP2009544703 A5 JP 2009544703A5 JP 2009521795 A JP2009521795 A JP 2009521795A JP 2009521795 A JP2009521795 A JP 2009521795A JP 2009544703 A5 JP2009544703 A5 JP 2009544703A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acids
- trka
- item
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83258606P | 2006-07-24 | 2006-07-24 | |
| US83665206P | 2006-08-10 | 2006-08-10 | |
| PCT/US2007/016589 WO2008013782A2 (en) | 2006-07-24 | 2007-07-24 | Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of sp35 or trka antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009544703A JP2009544703A (ja) | 2009-12-17 |
| JP2009544703A5 true JP2009544703A5 (cg-RX-API-DMAC7.html) | 2010-09-09 |
Family
ID=38982011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009521795A Pending JP2009544703A (ja) | 2006-07-24 | 2007-07-24 | Sp35またはTrkAアンタゴニストの投与により髄鞘形成、ニューロンの生存および希乏突起膠細胞の分化を促進するための方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8642040B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2068866A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2009544703A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008013782A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1569696T3 (da) * | 2002-11-21 | 2010-11-15 | Bayhill Therapeutics Inc | Fremgangsmåder og immunmodulatoriske nukleinsyrepræparater til forebyggelse og behandling af sygdomme |
| PL1606409T3 (pl) | 2003-03-19 | 2011-02-28 | Biogen Ma Inc | Białko wiążące receptor Nogo |
| PT1776136E (pt) | 2004-06-24 | 2012-12-05 | Biogen Idec Inc | Tratamento de estados que envolvem desmielinização |
| SI1904104T1 (sl) | 2005-07-08 | 2013-12-31 | Biogen Idec Ma Inc. | Protitelesa SP35 in njihova uporaba |
| EP1959979A4 (en) * | 2005-11-04 | 2010-01-27 | Biogen Idec Inc | PROCESS FOR PROMOTING AXON GROWTH AND SURVIVAL OF DOPAMINERGIC NEURONS |
| US20090175872A1 (en) * | 2005-12-02 | 2009-07-09 | Biogen Idec Ma Inc. | Treatment of Conditions Involving Demyelination |
| EP2068866A4 (en) | 2006-07-24 | 2010-04-07 | Biogen Idec Inc | METHODS FOR PROMOTING MYELINIZATION, NEURONAL SURVIVAL AND DIFFERENTIATION OF OLIGODENDROCYTES BY ADMINISTERING SP35 OR TRKA ANTAGONISTS |
| US8128926B2 (en) | 2007-01-09 | 2012-03-06 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
| CA2701189C (en) * | 2007-10-11 | 2017-05-16 | Biogen Idec Ma Inc. | Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists |
| WO2009061500A1 (en) * | 2007-11-08 | 2009-05-14 | Biogen Idec Ma Inc. | Use of lingo-4 antagonists in the treatment of conditions involving demyelination |
| US20110118340A1 (en) * | 2008-02-08 | 2011-05-19 | Muthiah Manoharan | Delivery of rnai constructs to oligodendrocytes |
| EP2315779A2 (en) | 2008-07-09 | 2011-05-04 | Biogen Idec MA Inc. | Compositions comprising antibodies to lingo or fragments thereof |
| EP2580238A1 (en) * | 2010-06-09 | 2013-04-17 | Zymogenetics, Inc. | Dimeric vstm3 fusion proteins and related compositions and methods |
| US9783601B2 (en) | 2010-12-01 | 2017-10-10 | Alderbio Holdings Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| WO2012149024A2 (en) | 2011-04-28 | 2012-11-01 | Mayo Foundation For Medical Education And Research | Dna aptamers for promoting remyelination |
| US9796780B2 (en) | 2012-05-14 | 2017-10-24 | Biogen Ma Inc. | LINGO-2 antagonists for treatment of conditions involving motor neurons |
| US9699433B2 (en) | 2013-01-24 | 2017-07-04 | Yuchen Zhou | Method and apparatus to produce re-focusable vision with detecting re-focusing event from human eye |
| WO2016112270A1 (en) | 2015-01-08 | 2016-07-14 | Biogen Ma Inc. | Lingo-1 antagonists and uses for treatment of demyelinating disorders |
| US10118904B2 (en) | 2015-06-05 | 2018-11-06 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of Demyelinating Diseases |
| US11185555B2 (en) | 2016-04-11 | 2021-11-30 | Noah James Harrison | Method to kill pathogenic microbes in a patient |
| WO2018106643A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
| WO2018106641A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pyrazoles for the treatment of demyelinating diseases |
| WO2018106646A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazoles for the treatment of demyelinating diseases |
| KR101878925B1 (ko) * | 2017-01-25 | 2018-07-16 | 한국과학기술연구원 | 희소돌기아교세포 분화용 조성물 및 이를 이용한 희소돌기아교세포 분화방법 |
| AR114110A1 (es) | 2018-02-28 | 2020-07-22 | Lilly Co Eli | Anticuerpo anti-trka |
| WO2020072456A1 (en) * | 2018-10-02 | 2020-04-09 | Case Western Reserve University | Compounds for treating myelin related disorders |
| WO2020118218A1 (en) | 2018-12-06 | 2020-06-11 | Mayo Foundation For Medical Education And Research | Short dna aptamers and methods for promoting remyelination |
| CN113481204B (zh) * | 2021-07-02 | 2022-08-12 | 湖南赛奥维生物技术有限公司 | 一种蛋白的核酸适配体、其衍生物及其应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5219837A (en) | 1990-06-21 | 1993-06-15 | Trustees Of The University Of Pennsylvania | Method of stimulating myelination of cells |
| US5468872A (en) * | 1993-09-16 | 1995-11-21 | Cephalon, Inc. | K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders |
| GB9402331D0 (en) | 1994-02-07 | 1994-03-30 | Univ Mcgill | Nerve growth factor structural analogs and their uses |
| DK0790246T3 (da) | 1994-10-25 | 2002-03-18 | Toyama Chemical Co Ltd | Middel til potensering af nervevækstfaktoraktivitet indeholdende 1,2-ethandiolderivat eller salt deraf |
| GB9525180D0 (en) | 1995-12-08 | 1996-02-07 | Univ Mcgill | Design of hormone-like antibodies with agonistic and antagonistic fuctions |
| JP2000501416A (ja) * | 1996-04-26 | 2000-02-08 | ユニバーシティー オブ オタワ | ニューロン病を治療し予防するための、治療法および薬物のスクリーニング法 |
| WO1997040847A1 (en) | 1996-04-26 | 1997-11-06 | University Of Ottawa | Therapeutic and drug screening methods for the treatment and prevention of neuronal disease |
| AU721942B2 (en) | 1996-06-25 | 2000-07-20 | Cephalon, Inc. | Use of K-252A derivative for the treatment of peripheral or central nerve disorders, and cytokine overproduction |
| FR2776661B1 (fr) * | 1998-03-26 | 2002-04-05 | Centre Nat Rech Scient | Polypeptide immunoreactif du recepteur trka du ngf et utilisations |
| US7282482B2 (en) | 1998-04-08 | 2007-10-16 | The Regents Of The University Of California | NGF for the prevention of demyelination in the nervous system |
| US7119165B2 (en) | 2000-01-12 | 2006-10-10 | Yale University | Nogo receptor-mediated blockade of axonal growth |
| HUP0203863A3 (en) | 2000-01-12 | 2008-03-28 | Univ Yale | Nogo receptor-mediated blockade of axonal growth |
| WO2001052843A1 (en) | 2000-01-18 | 2001-07-26 | Mcgill University | β-TURN PEPTIDOMIMETIC CYCLIC COMPOUNDS |
| AU2002327164A1 (en) | 2001-01-29 | 2002-12-09 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| BR0206985A (pt) | 2001-01-29 | 2005-04-19 | Idec Pharma Corp | Anticorpos modificados e métodos de uso |
| ATE469913T1 (de) | 2002-08-10 | 2010-06-15 | Univ Yale | Antagonisten des nogo-rezeptors |
| US6919426B2 (en) | 2002-09-19 | 2005-07-19 | Amgen Inc. | Peptides and related molecules that modulate nerve growth factor activity |
| US20040186044A1 (en) * | 2002-11-06 | 2004-09-23 | Cosgaya Jose Miguel | Modulation of myelination by interaction with P75 and TRK receptors |
| PL1606409T3 (pl) | 2003-03-19 | 2011-02-28 | Biogen Ma Inc | Białko wiążące receptor Nogo |
| JP2007501612A (ja) | 2003-08-07 | 2007-02-01 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Nogo受容体アンタゴニスト |
| PT1776136E (pt) | 2004-06-24 | 2012-12-05 | Biogen Idec Inc | Tratamento de estados que envolvem desmielinização |
| EP1789070B1 (en) | 2004-08-03 | 2012-10-24 | Biogen Idec MA Inc. | Taj in neuronal function |
| CA2609077A1 (en) | 2005-05-16 | 2006-12-28 | Mcgill University | Lgi, lingo and p75ntr family members: novel modulators of neuronal growth |
| SI1904104T1 (sl) | 2005-07-08 | 2013-12-31 | Biogen Idec Ma Inc. | Protitelesa SP35 in njihova uporaba |
| US20090175846A1 (en) | 2005-10-27 | 2009-07-09 | Biogen Idec Ma Inc | Oligodendrocyte-Myelin Glycoprotein Compositions and Methods of Use Thereof |
| EP1959979A4 (en) | 2005-11-04 | 2010-01-27 | Biogen Idec Inc | PROCESS FOR PROMOTING AXON GROWTH AND SURVIVAL OF DOPAMINERGIC NEURONS |
| US20090175872A1 (en) | 2005-12-02 | 2009-07-09 | Biogen Idec Ma Inc. | Treatment of Conditions Involving Demyelination |
| CN101405297A (zh) | 2006-02-03 | 2009-04-08 | 惠氏公司 | Lingo-1结构 |
| WO2007098283A2 (en) | 2006-02-27 | 2007-08-30 | Biogen Idec Ma Inc. | Use of antagonists of maif receptor complex molecules and neurotrophic factors for treatment of neurological diseases and disorders |
| EP2068866A4 (en) | 2006-07-24 | 2010-04-07 | Biogen Idec Inc | METHODS FOR PROMOTING MYELINIZATION, NEURONAL SURVIVAL AND DIFFERENTIATION OF OLIGODENDROCYTES BY ADMINISTERING SP35 OR TRKA ANTAGONISTS |
| CN103351437A (zh) | 2006-11-17 | 2013-10-16 | 诺瓦提斯公司 | Lingo结合分子及其制药用途 |
| US8128926B2 (en) | 2007-01-09 | 2012-03-06 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
| CA2701189C (en) | 2007-10-11 | 2017-05-16 | Biogen Idec Ma Inc. | Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists |
| ES2464459T3 (es) * | 2008-06-25 | 2014-06-02 | H. Lundbeck A/S | Modulación del sistema receptor Trpv:receptor de dominio Vps 10p para el tratamiento del dolor |
| EP2315779A2 (en) | 2008-07-09 | 2011-05-04 | Biogen Idec MA Inc. | Compositions comprising antibodies to lingo or fragments thereof |
-
2007
- 2007-07-24 EP EP07810708A patent/EP2068866A4/en not_active Withdrawn
- 2007-07-24 US US12/375,117 patent/US8642040B2/en not_active Expired - Fee Related
- 2007-07-24 WO PCT/US2007/016589 patent/WO2008013782A2/en not_active Ceased
- 2007-07-24 JP JP2009521795A patent/JP2009544703A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011500566A5 (cg-RX-API-DMAC7.html) | ||
| JP2010518007A5 (cg-RX-API-DMAC7.html) | ||
| US6531295B1 (en) | Synthetic constructs encoding syndecan | |
| EP3169784B1 (en) | Rnai compositions to treat apoc3-related diseases | |
| US6844168B1 (en) | Compositions comprising polynucleotides encoding human fibroblast growth factor receptor and uses thereof | |
| Thomas et al. | Molecular cloning of the fMet-Leu-Phe receptor from neutrophils | |
| US7205387B2 (en) | Recombinant polypeptide useful for neurotrophin receptor mediated gene delivery and as neurotrophin agonist | |
| AU2020280438B2 (en) | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use | |
| US20090215814A1 (en) | Method of inhibiting neurotrophin-receptor binding | |
| CA3225542A1 (en) | Oligonucleotide conjugates targeted to the transferrin receptor | |
| EP3101029A1 (en) | Variants of activin iib receptor polypeptides and uses thereof | |
| US20090305951A1 (en) | Compounds capable of affecting differentiation, proliferation, regeneration, plasticity and survival cells | |
| NZ568705A (en) | Methods for promoting neurite outgrowth and survival of dopaminergic neurons | |
| EP4602164A2 (en) | Small interfering rna targeting c3 and uses thereof | |
| Lappi | Tumor targeting through fibroblast growth factor receptors | |
| Wilkemeyer et al. | Alcohol inhibition of cell adhesion in BMP‐treated NG108‐15 cells | |
| Nakayama et al. | α4 is a major acetylcholine binding subunit of cholinergic ligand affinity-purified nicotinic acetylcholine receptor from rat brains | |
| US20080254023A1 (en) | Treating Gliosis, Glial Scarring, Inflammation or Inhibition of Axonal Growth in the Nervous System by Modulating Eph Receptor | |
| US20090130701A1 (en) | Novel sequence variants of multi-drug resistance genes, mdr1 and mrp1, and recombinant cells expressing mrp1 and mdr1 for assessment of drug penetration and disposition | |
| Karle et al. | Antisense oligonucleotide to GABAA receptor γ2 subunit induces loss of neurones in rat hippocampus | |
| US20050069537A1 (en) | Survical promoting ncam binding and ncam ligand binding compounds | |
| Ko et al. | Cyclic AMP regulates basement membrane heparan sulfate proteoglycan, perlecan, metabolism in rat glomerular epithelial cells | |
| US6699968B1 (en) | Construction and use of synthetic constructs encoding syndecan | |
| US6423827B1 (en) | Limbic system-associated membrane protein | |
| US20070116702A1 (en) | Survival promoting NCAM binding and MCAM ligand binding compounds |